ReferenceID 5607
Limonin, an AMPK Activator, Inhibits Hepatic Lipid Accumulation in High Fat Diet Fed Mice
Front Pharmacol
NAFLD is the most prevalent liver disease in human history. The treatment is still limited yet. In the current study, we reported that limonin inhibited hepatic lipid accumulation and fatty acid synthesis in HFD fed mice
Relationship Network
Interactive first-hop connections across herbs, ingredients, formulas, targets, diseases, symptoms, syndromes, evidence, and monographs.
Click a node to open it in a new tab
Ingredient: 1Reference: 1Links: 1
Arranging relationship network...
Record Fields
Scalar fields from the final reference record.
- Reference Id
- 5607
- Evidence Id
- 22197
- Core Evidence Id
- 22197
- Source Reference Id
- 4432
- Herb2 Reference Id
- HBREF005229
- Subject Paper Key
- HBIN033253_35140621
- Pubmed Id
- 35140621
- Doi
- 10.3389/fphar.2022.833705
- Paper Title
- Limonin, an AMPK Activator, Inhibits Hepatic Lipid Accumulation in High Fat Diet Fed Mice
- Paper Abstract
- NAFLD is the most prevalent liver disease in human history. The treatment is still limited yet. In the current study, we reported that limonin inhibited hepatic lipid accumulation and fatty acid synthesis in HFD fed mice. Using AMPK inhibitor and AMPK deficient C. elegans , we revealed the effect was dependent on the activation of AMPK. We found that limonin activated AMPK through inhibition of cellular energy metabolism and increasing ADP:ATP ratio. Furthermore, the treatment of limonin induced AMPK mediated suppression of the transcriptional activity of SREBP1/2. Our study suggests that limonin may a promising therapeutic agent for the treatment of NAFLD.
- Journal
- Front Pharmacol
- Publish Year
- 2022
- Experiment Subject
- mouse; human
- Experiment Type
- Animal & Cell Experiment
- Phenotype Related
- Liver Disease
- Paper Title Cn
- Paper Title En
- Limonin, an AMPK Activator, Inhibits Hepatic Lipid Accumulation in High Fat Diet Fed Mice
- Bilingual Status
- semi_complete